Myrelez (Lanreotide Acetate)

Lanreotide acetate, the active ingredient in Myrelez, is a somatostatin analog presented as an injectable solution for subcutaneous use. It is indicated for the treatment of acromegaly and for symptom control of neuroendocrine (carcinoid) tumors in adult patients, helping to reduce excess hormone secretion.

GNH USA supplies Myrelez as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards, provides regulatory documentation, and offers reliable logistics support for global distribution.

Myrelez, a long‑acting somatostatin analog, is employed in endocrine disorders where excess hormone production drives disease, offering a therapeutic option for patients who require medical management beyond surgery.

Acromegaly: normalises elevated growth‑hormone and insulin‑like growth factor‑1 levels, leading to reduction of soft‑tissue swelling, joint pain, cardiovascular risk and improvement of disease‑related symptoms. Neuroendocrine tumors (carcinoid): suppresses secretion of serotonin and other vasoactive peptides, helping control flushing, diarrhoea and may stabilise tumour progression, thereby improving quality of life. GH‑secreting pituitary adenoma (post‑surgical): provides additional hormone control when surgery does not achieve remission.

Myrelez may cause a range of adverse reactions, from mild to serious. Patients should be aware of the following potential side effects.

Common Side Effects: - Injection site pain: mild to moderate discomfort or erythema at the subcutaneous injection site. - Diarrhoea: loose stools that may occur especially during treatment initiation. - Nausea: transient feeling of sickness, often mild and self‑limiting.

Serious or Rare Side Effects: - Gallstone formation: development of biliary stones that may cause abdominal pain or cholecystitis. - Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain and elevated enzymes. - Severe hyperglycaemia or hypoglycaemia: significant alterations in blood glucose requiring medical intervention.

Before and during treatment with Myrelez, certain precautions should be observed to ensure safety. - Assess tumor size: evaluate pituitary adenoma dimensions before initiating therapy. - Monitor glucose: regularly check blood glucose in diabetic or pre‑diabetic patients. - Screen for gallbladder disease: perform ultrasound if history of gallstones. - Check liver and kidney function: adjust dose if severe impairment is present. - Avoid in hypersensitivity: discontinue if an allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Lanreotide acetate can interact with other medicines; some combinations should be avoided while others require careful monitoring.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin) may markedly reduce lanreotide exposure. - Concurrent octreotide therapy can increase risk of gallstone formation. - Co‑administration with insulin or sulfonylureas may exacerbate hyperglycaemia.

Moderate Interactions (Monitor Closely): - Dopamine agonists (e.g., cabergoline) may alter hormonal control; monitor levels. - QT‑prolonging agents (e.g., macrolides) require ECG monitoring for arrhythmia risk. - Other somatostatin analogs may increase gastrointestinal side effects; observe tolerance.